FDA Perspectives: Common Deficiencies in Abbreviated New Drug Applications: Part 2: Description, Composition, and Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Perspectives: Common Deficiencies in Abbreviated New Drug Applications: Part 2: Description, Composition, and Excipients
FDA chemistry reviewers in the Office of Generic Drugs provide an overview of common deficiences cited throughout the Chemistry, Manufacturing, and Controls section of ANDAs.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 45-51

References

1. A. Srinivasan and R. Iser, Pharm. Technol. 34 (1) 50-59 (2010).

2. FDA, Inactive Ingredient Search for Approved Drug Products, http://www.accessdata.fda.gov/scripts/cder/iig/, accessed June 30, 2010.

3. FDA, Guidance for Industry: Immediate Release Dosage Forms, Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (SUPAC-IR) (Rockville, MD, Nov. 1995).

4. FDA, QbR Frequently Asked Questions (June 4, 2007).

5. FDA, Guidance for Industry: Submitting Documentation for the Manufacturing of and Controls for Drug Products (Rockville, MD, Feb. 1987).

6. FDA, Data Standards Manual (monographs), Dosage Form, CDER Data Element Number, C-DRG-00201 (Dec. 15, 2006)

7. FDA, "21 CFR 314 Applications for FDA Approval to Market a New Drug," [Content and Format of an Abbreviated New Drug Application, Sec. 314.94 (9)].

8. FDA, "Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)"

9. FDA, Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (Rockville, MD, May 18, 2005).

10. FDA, "21 CFR 73 Listing of Color Additives Exempt from Certification", [Synthetic Iron Oxide, Sec. 73.1200].

11. S. Borodkin and M. H. Yunker, Jrnl. of Pharma. Sci. 59 (4) 481-386 (1970).

12. R. C. Rowe, P.J. Shesky, and M. E. Quinn, Eds., Handbook of Pharmaceutical Excipients, 6th ed. (Pharmaceutical Press, July 31, 2009).

13. USP 32–NF 27 (USP, Rockville, MD, 2010).

14. FDA, "21 CFR 170 Food Additives–21 CFR 180 Food Additives Permitted in Food or in Contact with Food on an Interim Basis Pending Additional Study."

15. Food and Chemicals Codex 6 (USP, Rockville, MD, 2010).

16. IPEC-Americas, Excipient Master File Guide (Arlington, VA, 2004).

17. FDA, "21 CFR 211 Current Good Manufacturing Practice for Finished Pharmaceutical," [Testing and Approval or Rejection of Components, Drug Product Containers, and Closures, Sec. 211.84 (d) (2)].

This article represents the views of the authors and not of FDA.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here